Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-16 (Canceled)

Claim 17 (Currently Amended) An injectable formulation, comprising:

(a) particles comprising a biocompatible polymeric matrix, the matrix comprising a poly(lactide-co-glycolide);

(b) a biologically active polypeptide dispersed within the matrix; and

(c) an injection vehicle comprising an aggregation-reducing amount of hyaluronic acid dissolved in a physiological buffer.

Claims 18-19 (Canceled)

Claim 20 (Previously Presented) A method for administering a biologically active polypeptide, comprising:

injecting the formulation of claim 17 into a patient in need thereof through a 23-gauge or smaller needle,

wherein the particles have an average diameter of between about 5 and about 200 microns.

Claim 21 (Currently Amended) An injectable formulation, comprising:

(a) an aggregation-reducing amount of hyaluronic acid dissolved in a physiological buffer; and

(b) particles, comprising:

(i) a biologically active agent, and

(ii) a biocompatible polymeric matrix.

Claim 22 (Currently Amended) An injectable formulation ~~of claim 21~~, comprising:

(a) an aggregation-reducing amount of hyaluronic acid dissolved in a physiological buffer; and

(b) particles, comprising:

(i) a biologically active agent, and

(ii) a biocompatible polymeric matrix, wherein the concentration of hyaluronic acid is about 0.01 to about 0.8 percent weight per volume.

Claim 23 (Currently Amended) The injectable formulation of claim 21, wherein the hyaluronic acid is dissolved in a physiological buffer comprising physiological saline.

Claim 24 (Canceled)

Claim 25 (Currently Amended) The injectable formulation of claim 21, wherein the polymeric matrix comprises a blocked polymer ~~selected from the group consisting of blocked polymers and unblocked polymers~~.

Claim 26 (Currently Amended) The injectable formulation of claim 21, wherein the polymeric matrix comprises an unblocked polymer ~~selected from the group consisting of blocked polymers and unblocked polymers~~.

Claim 27 (Previously Presented) The injectable formulation of claim 21, wherein the polymer is a poly(lactide-co-glycolide).

Claim 28 (Previously Presented) The injectable formulation of claim 21, wherein the biologically active agent is a polypeptide.

Claim 29 (Previously Presented) The injectable formulation of claim 28, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), a glucagon-like peptide I(GLP-I), a nerve growth factor, an insulin-like growth factor, and an antibody.

Claim 30 (Previously Presented) The injectable formulation of claim 21, wherein the concentration of the polymeric matrix is about 1 mg/mL to about 500 mg/mL of formulation.

Claim 31 (Previously Presented) The injectable formulation of claim 21, wherein the concentration of the polymeric matrix is about 1 mg/mL to about 300 mg/mL of formulation.

Claim 32 (Canceled)

Claim 33 (Previously Presented) The injectable formulation of claim 21, wherein the hyaluronic acid is N-acylurea modified hyaluronic acid.

Claim 34 (Previously Presented) The injectable formulation of claim 21, wherein the hyaluronic acid is sodium hyaluronate.

Claim 35 (Previously Presented) The injectable formulation of claim 17, wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), a glucagon-like peptide I (GLP-I), a nerve growth factor, an insulin-like growth factor, and an antibody.

Claim 36 (Previously Presented) The injectable formulation of claim 29, wherein the polypeptide is an anti-vascular endothelial growth factor Fab (anti-VEGF Fab).

Claim 37 (Previously Presented) The injectable formulation of claim 35, wherein the polypeptide is an anti-vascular endothelial growth factor Fab (anti-VEGF Fab).

Claim 38 (New) A kit providing a system for injection comprising:

(a) particles, comprising:

(i) a biologically active agent, and

(ii) a biocompatible polymeric matrix;

(b) an injection vehicle comprising hyaluronic acid dissolved in a physiological buffer; and

(c) an injection device comprising a 23 gauge or smaller needle.

Claim 39 (New) A method for reducing aggregation of particles in an injectable particle formulation, comprising

adding an aggregation-reducing amount of hyaluronic acid to a formulation comprising polymeric particles comprising:

(i) a biologically active agent, and

(ii) a biocompatible polymeric matrix;

wherein aggregation of the particles during injection is reduced as compared with a control formulation.